A Phase I/II Study Of PI-88 In Advanced Malignancies (Phase I), And In Advanced Melanoma(Phase II).
Latest Information Update: 29 Jun 2022
Price :
$35 *
At a glance
- Drugs Muparfostat (Primary)
- Indications Cancer; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Cellxpert Biotechnology
- 22 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 27 Sep 2005 New trial record.